Incyte — Apr 28, 2026 release

2026 Financial Guidance Incyte’s guidance for the fiscal year 2026 is summarized below. Incyte is reaffirming its guidance across all categories. Current Total net sales $4,770 - $4,940 million Jakafi net sales (1) $3,220 - $3,270 million Opzelura net sales (2) $750 - $790 million Hematology and Oncology net sales (3) $800 - $880 million Total GAAP R&D and SG&A operating expenses $3,495 - $3,675 million Total Non-GAAP R&D and SG&A operating expenses (4) $3,205 - $3,375 million 1 Includes the initial launch of Jakafi XR 2 Includes net sales for moderate atopic dermatitis in Europe which is anticipated to be approved in the second half of 2026. 3 Pemazyre ® (pemigatinib) in the U.S., Canada, Europe, Japan, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America (LatAm); Niktimvo and Monjuvi in the U.S.; Zynyz in the U.S., Europe and Japan; Iclusig ® (ponatinib) in Europe and MEA; and Minjuvi (tafasitamab) in Canada, Europe, Japan, APAC, MEA and LatAm. 4 Adjusted to exclude the estimated cost of stock-based compensation. Conference Call and Webcast Information Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13759527. If you are unable to participate, a replay of the conference call will be available for 90 days. The replay dial-in number for